CADL

Candel Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Manning Paul BDirector
$3.0M550.5k shares
BuyFeb 23, 2026
$5.45
--
Nichols William GarrettChief Medical Officer
$6.5k937 shares
SellJul 28, 2025
$6.98
--
Nichols William GarrettChief Medical Officer
$3.9k781 shares
SellJun 30, 2025
$5.04
--
Tak Paul PeterDirector, Officer: Chief Executive Officer
$3.6k400 shares
SellMar 19, 2025
$9.00
--
Nichols William GarrettChief Medical Officer
$397k45.3k shares
SellMar 18, 2025
$8.76
--
Barone FrancescaChief Scientific Officer
$282k32.1k shares
SellMar 18, 2025
$8.76
--

News

globenewswire.comCandel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancerglobenewswire.comJun 2globenewswire.comCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 1globenewswire.comCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 1marketbeat.comCandel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Datamarketbeat.comMay 20zacks.comWall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Tradezacks.comMay 19
CADL smart money exposure | 交易笔记